Injexate (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a cofactor in DNA synthesis. By limiting nucleotide formation, it reduces the proliferation of immune cells and cancer cells, and also increases adenosine levels that help dampen inflammation.

The specific dose of Injexate is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment response. Dosage regimens can vary widely, and the prescriber will tailor the schedule to achieve optimal therapeutic effect while monitoring safety.

Methotrexate is generally contraindicated during pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug may be excreted in milk, so breastfeeding is usually discouraged unless the benefits outweigh the risks.

To order Injexate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with biologic agents, methotrexate is a small‑molecule drug that is less expensive and can be administered subcutaneously. It has a well‑established efficacy profile for autoimmune diseases but may require more laboratory monitoring for liver and blood‑cell effects. Biologics often have different safety considerations, such as infection risk.

Injexate should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability and ensure proper temperature control during transport and storage.

Injexate is given by subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to reduce irritation, and the medication must be prepared according to aseptic technique. Administration is performed by a healthcare professional or trained patient under medical supervision.

The most serious risks include severe liver toxicity, pulmonary fibrosis, and bone‑marrow suppression leading to pancytopenia. Patients should be monitored regularly for liver enzymes, respiratory symptoms, and complete blood counts to detect these complications early.

Injexate should not be used by individuals with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, or those who are pregnant or planning pregnancy without adequate contraception. Caution is also advised for patients with pre‑existing blood‑cell disorders.